Kamada Stock Earnings Estimates Decreased by Sidoti

Kamada Ltd. (NASDAQ:KMDA) – Investment analysts at Sidoti cut their Q3 2028 earnings per share estimates for Kamada in a research note issued on Friday, September 25th. Sidoti analyst J. Sidoti now expects that the biotechnology company will earn $0.13 per share for the quarter, down from their prior estimate of $0.15. The consensus estimate for Kamada’s current full-year earnings is $0.48 per share.

Several other equities research analysts have also commented on the stock. Wall Street Zen raised shares of Kamada from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Benchmark reiterated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. UBS Group reiterated a “buy” rating and set a $15.00 target price on shares of Kamada in a report on Friday, September 18th. William Blair set a $15.00 price target on Kamada in a research report on Tuesday, July 21st. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research note on Tuesday, September 22nd. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Kamada presently has an average rating of “Buy” and a consensus price target of $13.50.

Kamada Price Performance

Shares of Kamada stock opened at $8.31 on Friday. Kamada has a 1 year low of $6.50 and a 1 year high of $9.35. The firm has a market cap of $477.87 million, a price-to-earnings ratio of 21.87, a PEG ratio of 0.70 and a beta of 0.89. The company has a 50-day moving average of $8.01 and a 200 day moving average of $7.89.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. Kamada had a return on equity of 8.37% and a net margin of 11.60%.The business had revenue of $54.92 million during the quarter, compared to analyst estimates of $50.84 million.

Kamada Cuts Dividend

The company also recently declared an annual dividend, which was paid on Thursday, September 17th. Investors of record on Thursday, August 27th were paid a $0.17 dividend. This represents a yield of 206.0%. The ex-dividend date was Thursday, August 27th. This is a negative change from Kamada’s previous annual dividend of $0.25. Kamada’s dividend payout ratio (DPR) is presently 31.58%.

Institutional Trading of Kamada

A hedge fund recently raised its stake in Kamada stock. Aristides Capital LLC grew its position in shares of Kamada Ltd. (NASDAQ:KMDA) by 4.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,491 shares of the biotechnology company’s stock after buying an additional 1,476 shares during the quarter. Aristides Capital LLC owned 0.06% of Kamada worth $288,000 as of its most recent filing with the Securities & Exchange Commission. 20.38% of the stock is owned by institutional investors.

About Kamada

Kamada Ltd. is an Israeli biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapies. The company’s products are designed to treat rare diseases, immune deficiencies and other serious medical conditions, with an emphasis on specialty biologic medicines and immunoglobulin-based treatments.

Kamada’s portfolio includes Glassia, an alpha-1 antitrypsin augmentation therapy for patients with alpha-1 antitrypsin deficiency; KEDRAB, a human rabies immune globulin used for post-exposure prophylaxis; WINRHO SDF, an immune globulin product; and CYTOGAM, a cytomegalovirus immune globulin.